Get the Stockscreener App
10.21
2.76%
-0.29
After Hours:
10.21
Iteos Therapeutics Inc stock is traded at $10.21, with a volume of 690.15K.
It is down -2.76% in the last 24 hours and down -39.41% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$10.50
Open:
$10.5
24h Volume:
690.15K
Relative Volume:
1.40
Market Cap:
$383.48M
Revenue:
$127.70M
Net Income/Loss:
$-108.14M
P/E Ratio:
-12.45
EPS:
-0.82
Net Cash Flow:
$-117.52M
1W Performance:
-3.68%
1M Performance:
-39.41%
6M Performance:
-25.15%
1Y Performance:
-6.76%
1-Day Range:
$9.93
$10.93
1-Week Range:
$9.93
$10.93
52-Week Range:
$8.20
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
156,894 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Bought by Clearline Capital LP - Defense World
156,894 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Bought by Clearline Capital LP - MarketBeat
There is no way ITeos Therapeutics Inc (ITOS) can keep these numbers up - SETE News
ITeos Therapeutics Inc (ITOS) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
A closer look at ITeos Therapeutics Inc (ITOS)’s stock price trends - US Post News
Renaissance Technologies LLC Sells 157,700 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Rhumbline Advisers Increases Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Renaissance Technologies LLC Has $8.30 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Analytical Lens: Exploring ITeos Therapeutics Inc (ITOS)’s Financial Story Through Ratios - The Dwinnex
(ITOS) Investment Report - Stock Traders Daily
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Holdings Lifted by Victory Capital Management Inc. - Defense World
Bank of New York Mellon Corp Has $1.80 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
JPMorgan maintains Overweight rating on iTeos amid TIGIT data By Investing.com - Investing.com Canada
Wedbush Weighs in on iTeos Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:ITOS) - Defense World
FY2027 Earnings Estimate for iTeos Therapeutics, Inc. Issued By Wedbush (NASDAQ:ITOS) - MarketBeat
iTeos Therapeutics (NASDAQ:ITOS) Stock Rating Reaffirmed by HC Wainwright - Defense World
View from ESMO: iTeos data keep TIGIT alive, for now - BioCentury
Balance Sheet Breakdown: ITeos Therapeutics Inc (ITOS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
ITeos Therapeutics Inc (ITOS) Stock: A Year of Market Fluctuations - The InvestChronicle
ESMO 24: GSK and iTeos Chalk Up Much-Needed Win For TIGIT - Scrip
Taking on analysts’ expectations and winning: ITeos Therapeutics Inc (ITOS) - SETE News
ITOS’s valuation metrics: A comprehensive analysis - US Post News
ESMO 2024: iTeos shares tumble despite TIGIT:PD-1 doublet promise - The Pharma Letter
iTeos Therapeutics' (ITOS) Buy Rating Reiterated at HC Wainwright - MarketBeat
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC - BioSpace
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study - Marketscreener.com
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study - Morningstar
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study - MarketWatch
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC - Yahoo Finance
Los Angeles Capital Management LLC Sells 4,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
ESMO: GSK, iTeos bring some optimism back to TIGIT - pharmaphorum
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT - Seeking Alpha
iTeos annonce un taux de réponse objective cliniquement significatif observé à chaque dose lors de l’analyse intermédiaire de suivi de l’étude GALAXIES Lung-201 portant sur l’association belrestotug + dostarlimab dans le traitement de première ligne des patients atteints d’un cancer du poumon non à petites cellules et présentant un taux de PD-L1 élevé - GlobeNewswire Inc.
TIGIT drug from iTeos shrinks lung tumors in trial - BioPharma Dive
TIGIT drug from iTeos shrinks lung tumors in trial - Yahoo Finance
GSK, iTeos lung cancer drug outperforms Jemperli (NASDAQ:ITOS) - Seeking Alpha
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - StockTitan
iTeos Announces Clinically Meaningful Objective Response - GlobeNewswire
ITeos Therapeutics Inc Inc. (ITOS) Price Performance: A Technical Analysis Perspective - The InvestChronicle
EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures - TT Nyhetsbyrån
A stock that deserves closer examination: ITeos Therapeutics Inc (ITOS) - US Post News
iTeos Therapeutics (NASDAQ:ITOS) Sees Strong Trading Volume - MarketBeat
Ratios Uncovered: Breaking Down ITeos Therapeutics Inc (ITOS)’s Trailing Twelve Months Metrics - The Dwinnex
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Allspring Global Investments Holdings LLC Decreases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Trading Up 8.2% - MarketBeat
A History of Outperforming Analyst Forecasts and Beating the Odds: ITeos Therapeutics Inc (ITOS) - SETE News
509,303 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Acquired by Candriam S.C.A. - MarketBeat
Candriam S.C.A. Invests $7.56 Million in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):